Zanubrutinib | MedChemExpress (MCE)-产品咨询-资讯-生物在线

Zanubrutinib | MedChemExpress (MCE)

作者:MedChemExpress LLC 暂无发布时间 (访问量:1769)

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。

Zanubrutinib

CAS No. : 1691249-45-2

MCE 国际站:Zanubrutinib

产品活性:Zanubrutinib (BGB-3111) 是一个选择性的具有口服活性的 Bruton tyrosine kinase (Btk) 抑制剂 (IC50: 0.3 nM)。

研究领域:Protein Tyrosine Kinase/RTK

作用靶点:Btk

In Vitro: Zanubrutinib (BGB-3111) is a selective Bruton tyrosine kinase (BTK) inhibitor. In both biochemical and cellular assays, Zanubrutinib demonstrates nanomolar BTK inhibition activity. In several MCL and DLBCL cell lines, Zanubrutinib inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with PCI-32765, Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK.

In Vivo: Zanubrutinib (BGB-3111) induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts, Zanubrutinib at 2.5 mg/kg BID shows similar activity as PCI-32765 at 50 mg/kg QD. In the systemic model, the median survival of Zanubrutinib 25 mg/kg BID group is significantly longer than those of both PCI-32765 50 mg/kg QD and BID groups. In an ABC-subtype DLBCL (TMD-8) subcutaneous xenograft model, Zanubrutinib also demonstrates better anti-tumor activity than PCI-32765. Preliminary 14-day toxicity study in rats shows that Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250 mg/kg/day.

相关产品:Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Rare Diseases Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Cysteine Targeted Covalent Library  |  Autoimmune Disease Compound Library  |  Highly Selective Inhibitors Library  |  Anti-Hematopathy Compound Library  |  Bioactive Compound Library Max  |  Ibrutinib  |  Acalabrutinib  |  Pirtobrutinib  |  Fenebrutinib  |  Remibrutinib  |  Tolebrutinib  |  NX-2127  |  Rilzabrutinib  |  Orelabrutinib  |  Nemtabrutinib  |  Sunvozertinib  |  Tirabrutinib  |  Spebrutinib  |  Ibrutinib-biotin  |  NX-5948  |  QL47  |  MT-802  |  (Z)-LFM-A13  |  Branebrutinib  |  CGI-1746  |  SJF620  |  (±)-Zanubrutinib  |  Luxeptinib  |  Vecabrutinib  |  BMX-IN-1  |  Avitinib maleate  |  Ibrutinib-MPEA

热门产品线:重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
•   产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
•   提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
•   设有专业的实验中心和严格的质控、验证体系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
•   产品的生物活性多经各国客户实验验证;
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
•   专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
•   与世界各大制药公司及知名科研机构建立了长期的合作。

类药多样性化合物库
顾客使用MCE产品发表的科研文献
一站式药筛新体验
MCE 您身边的生物活性分子大师 | 抑制剂、激动剂、化合物库
重组蛋白 | 高纯度、高稳定性
磁珠
MCE Hotline: 4008203792 | 中国现货 - 全球文献引用 - 高纯度高品质 - 全方位技术支持
MedChemExpress LLC 商家主页

地 址: 上海市浦东新区张衡路1999弄3号楼

联系人: 销售部

电 话: 021-58955995

传 真: 021-53700325

Email:sales@medchemexpress.cn

相关咨询
ADVERTISEMENT